XVARY Composite Score
54
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Ashland sells specialty ingredients that end up in your pills, skin creams, buildings, and industrial chemicals.
How it gets paid
Last year Ashland made $1.8B in revenue. Life Sciences was the main engine at $0.67B, or 37% of sales.
Why growth slowed
Revenue fell 13.7% last year. $386 million of revenue matters more than the EPS beat because a shrinking top line makes turnaround math harder.
What just happened
Ashland printed $1.07 EPS versus a $0.35 estimate, but revenue still fell 5% vs. prior year.
At a Glance
B+ balance sheet — decent shape, but not bulletproof
5/100 earnings predictability — expect surprises
19.4x trailing p/e — priced about right
2.8% dividend yield — cash in your pocket every quarter
5.0% return on capital — nothing to write home about
XVARY composite: 54/100 — below average
What They Do
Ashland sells specialty ingredients that end up in your pills, skin creams, buildings, and industrial chemicals.
When your pill coating or skin cream formula already works, you do not casually swap ingredients. Reformulation risk (changing a formula that already passed testing) means delays, customer retesting, and potential product headaches. That stickiness helps support a business still doing $1.8 billion in annual revenue, even after sales fell 13.7%.
How They Make Money
$1.8B
annual revenue · their business grew -13.7% last year
Life Sciences
$0.67B
Personal Care
$0.45B
Specialty Additives
$0.40B
Intermediates
$0.28B
The Products That Matter
Pharma and nutrition ingredients
Life Sciences
part of a $1.8B company
this business sits inside a company that generated $1.8B in revenue, and the market keeps looking to life sciences for resilience while total sales still fell 13.7% last year.
defensive mix
Skin care and household ingredients
Personal Care
part of the core portfolio
investors are giving this piece some credit for stability, but the company still posted full-year EPS of -$17.87. resilience needs to show up in reported earnings, not just the story.
rerating bet
Broader additives and intermediates
Specialty Additives and Intermediates
demand has been weak
this is the part of the portfolio management called out as under pressure, and when companywide revenue is down 13.7%, you do not need a segment breakout to know demand is the issue.
cyclical drag
Key Numbers
$3.20
fy2027 eps est
$2B
fy2027 rev est
19.4x
trailing p/e
2.8%
dividend yield
Financial Health
B+
Strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 70 / 100
- long-term debt $1.4B (33% of capital)
- net profit margin 7.1% — keeps 7 cents of every dollar in revenue
- return on equity 6% — $0.06 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total Return vs. Market
You invested $10000 in ASH 3 years ago → it's now worth $6340.
The index would have given you $13880.
source: institutional data · total return
What Just Happened
beat estimates
Ashland printed $1.07 EPS versus a $0.35 estimate, but revenue still fell 5% vs. prior year.
The quarter looked better than feared on earnings, but the top line stayed under pressure. Latest quarterly revenue was $386 million, and gross margin was 27.2%.
$386M
revenue
$1.07
eps
27.2%
gross margin
the number that mattered
$386 million of revenue matters more than the EPS beat because a shrinking top line makes turnaround math harder.
-
Investors appear to be giving ashland stock a resiliency premium.
-
The equity has bounced off the lows it experienced last year, rising almost 25% since our latenovember report.the issue’s recovery is surprising given the fact that fiscal first-quarter revenues were down vs. prior year for the fifth successive quarter (year ends september 30th).
-
In addition, the company posted a loss, albeit a relatively small one.
-
Still, we don’t think this is justified considering such a huge leap in the stock price.the rebound was probably a result of investors thinking that the stock had been trading at book value plus cash per share for long enough, and that the life sciences’ and personal care businesses deserved a higher ebitda multiple for their resilience during tough economic times.
-
Specialty additives, and intermediates have been suffering from waning demand.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The top risk is continued demand weakness in specialty additives and intermediates.
Med
Demand stays weak
Sales already fell 13.7% last year, and management commentary still points to softness in specialty additives and intermediates.
impact: this touches the full $1.8B revenue base because weak volume anywhere in the portfolio shows up fast at this scale.
Med
Earnings stay messy
Earnings predictability is 5/100, quarterly EPS was -$0.26, and full-year EPS swung from $3.95 to -$17.87.
impact: if reported earnings keep lurching around like this, the stock does not get the benefit of the doubt.
Med
Balance sheet flexibility narrows
The balance sheet is B+, not broken, but $1.4B in long-term debt equals 33% of capital.
impact: leverage is manageable until growth stalls. then it starts limiting buybacks, deals, and patience.
Med
Legal and regulatory noise grows
The snapshot flags ongoing legal and regulatory proceedings, but disclosure here is thin. That alone is worth respecting.
impact: with earnings already volatile, even modest legal costs or distractions can matter more than usual.
Revenue fell 13.7% last year, full-year EPS dropped from $3.95 to -$17.87, and the 3–5 year target midpoint of $52 already sits 16% below the current $62.24. You do not need a disaster here to lose money.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Metric
Revenue trend
Five straight quarters of sales decline is the whole problem. If that streak ends, the rerating story gets real fast.
Trend
Whether the 25% bounce holds
A rebound without cleaner earnings can fade just as quickly as it arrived.
Risk
Legal and regulatory disclosures
This snapshot flags proceedings but does not give much detail. If the language gets more specific, pay attention.
Calendar
Next earnings print
You need to see whether $386M in quarterly revenue was the trough or just another stop on the way down.
Analyst Rankings
short-term outlook
average
momentum score 3 — middle of the pack. in human-speak, analysts do not see a clear short-term edge.
risk profile
average
stability score 3 — typical market risk. not especially safe, not especially wild.
chart momentum
average
technical score 3 — the chart is not screaming anything obvious despite the recent bounce.
earnings predictability
5 / 100
earnings predictability 5/100 — this is analyst language for "do not assume a smooth model."
Source: institutional data
Institutional Activity
146 buyers vs. 191 sellers in 3q2025. total institutional holdings: 42.6M shares.
Source: institutional data
Price Targets
3-5 year target range
$29
$75
$62
Current price
$52
Target midpoint · 16% from current · 3-5yr high: $100 (+60% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive